Study of drug utilization pattern in chronic kidney disease patients undergoing haemodialysis
Keywords:
Chronic Kidney disease, haemodialysis, drug utilization, WHO criteria, comorbidities.Abstract
Introduction: Chronic kidney disease (CKD) is a global threat to health, especially for developing countries because of an increasing incidence and poor outcome. Careful selection of drugs while prescribing in patients with CKD is necessary and the drug and its dose should be selected appropriately to avoid drug interactions, renal damage, adverse drug reactions and poor outcomes. However, errors in prescription in patients with CKD do occur. Hence it is important to study the drug utilization pattern in chronic kidney disease patients undergoing haemodialysis.
Materials and methods: A cross sectional, prospective observational study was carried out in the haemodialysis unit at a tertiary care hospital. Patient details like registration number, age, gender and medications were recorded in the Case Record Form. Prescribing indicators were evaluated as per WHO criteria.
Results: Out of 361study population 319 (88.37%) patients were having comorbidities and 42 (11.63%) patients were without any comorbidities. In total 2933 drugs were prescribed to study population and 8.12 drugs were prescribed per patient. Furosemide was the most commonly prescribed drug followed by amlodipine and sodium bicarbonate. Out of total prescribed drugs, 335 (11.4%) were antibiotics. Most commonly prescribed antibiotic was ceftriaxone. About 54.3% of drugs were prescribed by generic name. Out of total prescribed drugs, 2263 (77.2 %) drugs were listed in NELM.
Conclusion: This study provides an insight regarding utilization pattern of a wide variety of drug classes in CKD patients undergoing haemodialysis in a tertiary care hospital and suggests a possible improvement in prescribing practices in CKD patients.
Keywords: Chronic Kidney disease, haemodialysis, drug utilization, WHO criteria, comorbidities
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2021 International Journal of Pharmacological Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Author must Submit Copyright form After acceptance of Article